Holen Sie sich die Stockscreener-App
14.55
1.46%
0.21
Vorhandelsmarkt:
14.65
0.10
+0.69%
Schlusskurs vom Vortag:
$14.34
Offen:
$14.25
24-Stunden-Volumen:
1.33M
Relative Volume:
0.72
Marktkapitalisierung:
$1.73B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-3.7117
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
-5.52%
1M Leistung:
+5.28%
6M Leistung:
+6.13%
1J Leistung:
+47.72%
1-Tages-Spanne:
$14.10
$14.71
1-Wochen-Bereich:
$14.10
$15.89
52-Wochen-Spanne:
$7.86
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.55 | 1.84B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
Is Arcutis Biotherapeutics Inc. a good long term investmentFree Capital Growth Strategies - jammulinksnews.com
What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com
Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India
What analysts say about Arcutis Biotherapeutics Inc. stockTremendous portfolio expansion - Autocar Professional
(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st
Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
FDA News and Decisions: Midyear Updates - Dermatology Times
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN
(ARQT) Investment Analysis - news.stocktradersdaily.com
Arcutis Biotherapeutics - WBFF
Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria
Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus
ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan
Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia
Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):